IVAX offering up to $500M in senior notes

30 April 2001

IVAX Corp says that it is to offer up to $500 million of convertiblesenior subordinated notes, the proceeds of which will be used for acquisitions of businesses or products, R&D funding and general corporate purposes. The notes will have a 2008 maturity date and be redeemable after three years from issuance.

Major leap in first-quarter earnings

The company also noted that earnings including one-time items in the first quarter of 2001 reached $60.1 million compared with $26.7 million for the like, year-earlier period. Revenues rose 42% to $259.9 million, boosted by $50 million sales for Onxol, IVAX' generic version of Bristol-Myers Squibb's Taxol (paclitaxel).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight